Dataset Information

Screening pertactin-specific antibodies and evaluating competitive epitope recognition by native mass spectrometry

ABSTRACT: This study employs high-resolution native mass spectrometry (nMS) to define, compare, and mechanistically dissect the binding behavior of four therapeutic monoclonal antibodies (1E7, 2B1, 1F2, and 2E9) targeting the Bordetella pertussis antigen pertactin (Prn).

ORGANISM(S): Escherichia Coli Mus Musculus (mouse)

SUBMITTER: Jennifer S. Brodbelt

PROVIDER: PXD071705 | JPOST Repository | Fri Feb 13 00:00:00 GMT 2026

REPOSITORIES: jPOST

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	1E7_2B1_Prn_Competition%20experiment.RAW	Raw
	1E7_Prn_vT.RAW	Raw
	1E7_mAb_vT.RAW	Raw
	1F2_1E7_Prn_Competition%20experiment.RAW	Raw
	1F2_2B1_Prn_Competition%20experiment.RAW	Raw

Items per page:

1 - 5 of 20

Similar Datasets

Project description:Only 59% of Alaska Native people have been adequately screened for colorectal cancer (CRC) despite having the highest reported incidence of CRC in the world. A new at-home multi-target stool DNA screening test (MT-sDNA; Cologuard) with high sensitivity for pre-cancerous polyps and CRC is now available. MT-sDNA has not been tested for feasibility or acceptability within the Alaska tribal health care delivery system, and it is unknown whether use of this new test will increase Alaska Native CRC screening rates. The long-term study goal is to improve screening and reduce CRC-attributable mortality. The objective of this application is to test the effectiveness of MT-sDNA for increasing CRC screening in Alaska Native communities using a mixed methods, community-based participatory research (CBPR) approach. The study will be conducted in collaboration with regional Tribal health organizations responsible for providing health care to geographically remote Alaska Native communities. Although the proposed implementation strategy is evidence-informed and promising, it is novel in that MT-sDNA has not been evaluated in the tribal health setting or among rural/remote populations. Using the Social Ecological Model, the research will be multi-level, examining influence on patients, providers, and tribal health organizations (THOs). This research study will pursue two specific aims: (1) Identify patient-, provider-, and system-level factors associated with CRC screening preferences, uptake, and follow-up; and (2) test the effectiveness of graded intensity MT-sDNA intervention in the Alaska Native community setting. For the first aim, focus groups with Alaska Native people who are not adherent to CRC screening guidelines and interviews with healthcare providers will be used to identify factors for future intervention. For the second aim, a three-arm cluster randomized controlled trial (high intensity with patient navigation, medium intensity with mailed reminders, usual care) will provide evidence on the MT-sDNA usefulness (MT-sDNA sample quality and neoplastic yield) as well as the first data on MT-sDNA follow up adherence rates in the Alaska Native population, which will inform plans to scale-up the intervention model. This research has the potential to sustainably improve public health by increasing CRC screening rates among a rural/remote tribal population as well as provide a model for other integrated health systems that provide care to high-risk or underserved populations in the U.S. and worldwide.

Dataset Information

Screening pertactin-specific antibodies and evaluating competitive epitope recognition by native mass spectrometry

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets